What the endocannabinoid system actually does

The simplest accurate description is this: the ECS keeps things in range.

Your body runs on a continuous balancing act. Body temperature, blood pressure, blood sugar, sleep-wake cycles, immune response, pain perception, mood, appetite, fertility — every one of these has to stay within a livable range while everything around you constantly changes. Stress, food, sleep, season, infection, injury, hormone cycles, age. The biological term for the body's ongoing effort to hold itself in range against all of that is homeostasis. It is the most boring word in medical school and the most important word in your body.

The ECS is one of the body's primary instruments for maintaining homeostasis⁵. It does this with three components working together:

• Receptors embedded in cell membranes (CB1, CB2, and several others that respond to cannabinoid-shaped molecules)
• Endocannabinoids — molecules your body makes on demand, primarily anandamide and 2-AG
• Enzymes that build endocannabinoids when they're needed and break them back down when their work is done

The choreography matters more than the parts list. Endocannabinoids are not stored in advance the way some neurotransmitters are. They are synthesized on demand from lipid precursors in the cell membrane, released, allowed to do their job, and then enzymatically degraded so the signal does not run too long. This is one of the elegant features of the system — it is self-limiting by design⁶. Anandamide is broken down by an enzyme called FAAH (fatty acid amide hydrolase). 2-AG is broken down primarily by MAGL (monoacylglycerol lipase). Both enzymes are part of the system, not external to it.

When researchers in the 2000s started looking carefully at how endocannabinoid signaling works at synapses, they discovered something genuinely unusual. In most neural communication, the signal travels in one direction — the presynaptic neuron releases neurotransmitter, the postsynaptic neuron receives it. Endocannabinoids work in reverse. They are released from the postsynaptic neuron and travel back to the presynaptic side, where they bind CB1 receptors and quiet the original signal. This is called retrograde neurotransmission⁶. The body uses it to keep neural firing from running away with itself — a real-time braking system for excitatory signaling.

That braking function is part of why the ECS shows up in conversations about anxiety, pain, sleep, and inflammation. When the body needs to dial something back, the ECS is one of the systems it reaches for first.

The receptors, and where they live in your body

CB1 and CB2 are the two best-studied cannabinoid receptors, and they live in very different neighborhoods.

CB1 receptors are concentrated in the central nervous system — brain and spinal cord — with the densest expression in regions that handle memory, motor control, emotion, and reward¹. They are one of the most abundant G-protein-coupled receptors in the brain. CB1 binds THC well, which is why THC produces the cognitive and mood effects it does. CB1 also binds anandamide and 2-AG — your body's own ligands for the receptor — at lower intensity and with more controlled release.

CB2 receptors are concentrated outside the central nervous system — primarily on immune cells, in lymphoid tissue, in the gut, and in the skin². CB2 activation modulates inflammation, immune response, and pain perception at the peripheral level. CB2 has no significant psychoactive effects. It is the receptor most directly involved in inflammation control, and it is one of the reasons topical preparations applied to skin can do meaningful work without needing to cross the blood-brain barrier.

Both receptors share architecture and are part of the same family, but their signaling cascades are different and their distributions barely overlap. Think of CB1 as the central regulator and CB2 as the peripheral regulator — a useful simplification, even if biology resists clean lines.

And now the part where everyone gets it wrong. CBD — the compound most people associate with the wellness side of the cannabinoid conversation — has low direct binding affinity at CB1 and CB2 at the doses most people use⁸. It is a low-affinity, partially-active ligand at both, and can also act as a negative allosteric modulator at CB1. So how does CBD work?

The answer is that CBD acts through other receptors entirely. The most-studied of these are the TRP channels — transient receptor potential ion channels — which sit on cell membranes and respond to temperature, irritants, and certain plant compounds. Several TRP channels (TRPV1 in particular, but also TRPV2, TRPA1, and TRPM8) bind CBD with measurable affinity⁹. TRPV1 is the same receptor that responds to capsaicin in chili peppers. CBD also modulates serotonin receptors, adenosine signaling, and the enzyme FAAH — meaning it can raise your body's own anandamide levels by slowing the enzyme that breaks anandamide down¹⁰.

This is part of why "the ECS" is increasingly described in the literature as the endocannabinoidome — a broader interconnected network that includes the original CB1/CB2 receptors and a series of related receptors and signaling molecules that all use lipid-based messengers and overlap functionally with each other¹¹. The simple two-receptor picture is correct but incomplete. The actual picture is bigger, messier, wired through more of the body, and more interesting than the textbooks have caught up to.

A practical note for women reading this: TRP channels are expressed across nearly every tissue type in the body⁹. The communication routes the ECS uses are not specialized hardware found only in your brain or your immune system. They are wired through nearly every tissue you have. That has implications for what topical preparations can reach — and it is part of why a roll-on applied to skin is a serious pharmacological delivery route, not a cosmetic one.

Why this matters more after 40

So why am I writing about a balance system for women in perimenopause and menopause specifically? Because estrogen and the endocannabinoid system are tightly coupled — and when estrogen declines, the ECS does not just keep running quietly in the background like it did at thirty-two.

Several lines of research now establish that 17β-estradiol — the principal form of estrogen during reproductive years — directly modulates the endocannabinoid system.

Estradiol stimulates the enzyme NAPE-PLD, which is the enzyme that builds anandamide¹². Estradiol also inhibits FAAH, the enzyme that degrades anandamide. The net effect: when estrogen is high, anandamide tone tends to be high. When estrogen drops — across the menstrual cycle, across the perimenopausal transition, and into postmenopause — anandamide tone tends to drop with it. Estradiol also regulates CB1 expression in a region-specific way across the brain¹³, meaning the receptor density itself shifts with hormonal state.

The reproductive tissues themselves express ECS components throughout — ovary, uterus, fallopian tube, vaginal tissue, breast tissue all show CB1, CB2, and the enzymes that build and break down endocannabinoids¹⁴. Estrogen and the ECS regulate each other in a continuous feedback loop. When the loop loses its principal input — estrogen — the loop changes shape.

This is the bridge between I am not who I was a year ago and here is what is actually changing at the cellular level. The list of complaints — sleep that stopped working, mood that swings without warning, joints that hurt for no reason, skin that suddenly behaves like someone else's, the libido conversation nobody wants to have at the dinner table, brain fog you can feel in real time — overlaps almost completely with the list of systems the ECS regulates. That is not coincidence. It is the same system telling the same story from different angles.

And the data is starting to catch up to what women have been quietly figuring out on their own. A 2022 study published in Menopause found that 78.7% of peri- and postmenopausal women using medical cannabis reported using it specifically to target menopause symptoms¹⁵. That is not a clinical trial. It is a self-report survey, with all the limitations that implies. But it is a meaningful signal that women are reaching for cannabinoid support to address menopausal symptoms, ahead of the formal evidence base — and the mechanistic plausibility for why is real.

How phytocannabinoids enter this picture

Phytocannabinoids are plant-made compounds that interact with the same receptor systems the body uses for its own endocannabinoids. The cannabis plant produces over 100 of them. Many other plants also produce compounds that engage this system — copaiba, black pepper, hops, certain pine species, clove — though usually with fewer compounds and different proportions.

The four worth knowing by name:

• CBD (cannabidiol): The most-studied non-intoxicating cannabinoid. Engages TRP channels and modulates FAAH activity. Indirect ECS support rather than direct receptor binding⁸⁹¹⁰.
• THC (tetrahydrocannabinol): Binds CB1 directly. Produces the cognitive and mood effects associated with cannabis. Federally regulated.
• CBN (cannabinol): Forms when THC oxidizes. Lower CB1 affinity than THC. Has emerged in human RCT data as relevant for sleep¹⁶.
• β-caryophyllene: A terpene rather than a classical cannabinoid, but a confirmed selective CB2 agonist¹⁷. Found in copaiba, black pepper, clove, and rosemary. One of the few CB2-active compounds you can encounter in foods and topicals.

A note on what "full-spectrum" actually means. A full-spectrum hemp extract is one that contains not just CBD but the accompanying cannabinoids and terpenes present in the source plant — the integrated phytochemical matrix. The working hypothesis in the field — sometimes called the entourage effect — is that this integrated matrix produces different effects than isolated CBD alone¹⁸. The hypothesis has directional support and is still being actively refined in the literature. It is not yet definitively settled, but the comparative evidence is real.

This is what I have been doing with Rockstar Blends. Every formula in the line is built around full-spectrum hemp paired with botanical extracts chosen for the compounds they bring to the receptor system — copaiba for β-caryophyllene, black pepper for both β-caryophyllene and penetration enhancement, frankincense for AKBA and incensole acetate, and others. The point is not to pick one molecule and load it. The point is to assemble a coherent topical preparation that engages the system the body already uses, applied where the receptors are densely present.

What the research has not yet answered

I want to be specific about this section because this is the part where Rockstar Blends sets its own standard.

We do not have a menopause-specific randomized controlled trial of any phytocannabinoid for any specific symptom endpoint. The closest adjacent evidence:

• The Bonn-Miller 2024 CBN sleep RCT (n=293) and the Kolobaric 2024 CBN sleep RCT (n=1,020) both show CBN at modest doses improves sleep without next-day grogginess¹⁶¹⁹. These were adult populations with sleep disturbance — not menopause-specific.
• A 2022 Menopause survey documenting widespread peri- and postmenopausal cannabis use for menopausal symptoms¹⁵. This is observational self-report, not clinical evidence.
• Multiple animal studies and in vitro studies linking estrogen-ECS regulation to outcomes relevant to menopausal symptoms¹²¹³¹⁴. Mechanism, not clinical proof.

That is the state of the evidence as of mid-2026. There is real reason to take this seriously. There is also a clear, named gap that the field has not closed. The Rockstar Blends position is to operate honestly on top of that landscape — not to pretend the gap doesn't exist, and not to wait passively for someone else to fill it.

A second active area where I want to flag honest uncertainty is the clinical endocannabinoid deficiency framework — the proposal that some chronic conditions (migraine, fibromyalgia, IBS) reflect underlying ECS underactivity. The framework was proposed by Ethan Russo and has supporters in the field²⁰. It is not yet broadly accepted as a clinical diagnosis. We talk about supporting the system. We do not talk about treating a deficiency.

Why I do this work

When I started developing topical preparations from botanical extracts, I was thinking about my own lymphatic system and my own recovery. I was not thinking about cannabinoid receptors. The science caught up with what plant medicine practitioners had been doing for a long time, and what my doctor was teaching me to do for myself.

The reason I write posts like this one is that I want the women who come to Rockstar Blends to understand what is actually happening when they use what I make. You came here for the biology and the citations, not the tagline. You are smart, you are skeptical, you can smell hype from across the room, and you want the mechanism, the evidence, and the honest gaps. You deserve it that way.

The endocannabinoid system has been here the whole time. The science is real, it is moving fast, and the part of it that matters most for women my age is the part the menopause conversation is just beginning to catch up to.